Literature DB >> 32781201

Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure.

Florence Wong1, Salvatore Piano2, Virendra Singh3, Michele Bartoletti4, Rakhi Maiwall5, Carlo Alessandria6, Javier Fernandez7, Elza Cotrim Soares8, Dong Joon Kim9, Sung Eun Kim10, Monica Marino11, Julio Vorobioff12, Rita de Cassia Ribeiro Barea13, Manuela Merli14, Laure Elkrief15, Victor Vargas16, Aleksander Krag17, Shivaram Prasad Singh18, Laurentius Adrianto Lesmana19, Claudio Toledo20, Sebastian Marciano21, Xavier Verhelst22, Nicolas Intagliata23, Liane Rabinowich24, Luis Colombato25, Sang Gyune Kim26, Alexander Gerbes27, Francois Durand28, Juan Pablo Roblero29, Tony Bruns30, Eileen Laurel Yoon31, Marcos Girala32, Nikolaos T Pyrsopoulos33, Tae Hun Kim34, Sun Young Yim35, Adria Juanola36, Adrian Gadano20, Paolo Angeli37.   

Abstract

BACKGROUND & AIMS: Bacterial infections can trigger the development of organ failure(s) and acute-on-chronic liver failure (ACLF). Geographic variations in bacteriology and clinical practice could lead to worldwide differences in ACLF epidemiology, phenotypes and associated outcomes. Herein, we aimed to evaluate regional differences in bacterial infection-related ACLF in patients with cirrhosis admitted to hospital.
METHODS: This post hoc analysis included 1,175 patients with decompensated cirrhosis (with bacterial infection on admission or nosocomial infection) from 6 geographic regions worldwide. Clinical, laboratory and microbiological data were collected from the diagnosis of infection. Patients were followed-up for organ failure(s) and ACLF development according to the EASL-CLIF criteria from enrolment to discharge/death.
RESULTS: A total of 333 patients (28%) had ACLF at diagnosis of infection, while 230 patients developed ACLF after diagnosis of infection, resulting in an overall rate of bacterial infection related-ACLF of 48%, with rates differing amongst different geographic regions (38% in Southern Europe vs. 75% in the Indian subcontinent). Bacterial infection related-ACLF more frequently developed in younger patients (55 ± 13 vs. 58 ± 14 years), males (73% vs. 62%), patients with alcohol-related cirrhosis (59% vs. 45%) and those with a higher baseline MELD score (25 ± 11 vs. 16 ± 5) (all p <0.001). Spontaneous bacterial peritonitis, pneumonia or infections caused by extensively drug resistant (XDR) bacteria were more frequently associated with ACLF development. More patients with ACLF had a positive quick sequential organ failure assessment score and septic shock, resulting in a lower infection resolution rate (all p <0.001).
CONCLUSIONS: Bacterial infections, especially with XDR organisms, are associated with the highest risk of ACLF development, accounting for almost half of cases globally. Geographic differences result in variable epidemiology and clinical outcomes. LAY
SUMMARY: Bacterial infections can trigger a sudden deterioration in an otherwise stable cirrhotic patient, a condition known as acute-on-chronic liver failure or ACLF. This study has found that the development of ACLF following bacterial infection occurs most commonly in the Indian subcontinent and less so in Southern Europe. The common infections that can trigger ACLF include infection of the abdominal fluid, known as spontaneous bacterial peritonitis, pneumonia and by bacteria that are resistant to multiple antibiotics. Patients who develop ACLF following a bacterial infection have high death rates and are frequently unable to clear the infection.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  ACLF; Antibiotic resistance; Cirrhosis; Liver transplantation; MDR; Sepsis; XDR

Mesh:

Year:  2020        PMID: 32781201     DOI: 10.1016/j.jhep.2020.07.046

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  11 in total

1.  Bioenergetic Failure Drives Functional Exhaustion of Monocytes in Acute-on-Chronic Liver Failure.

Authors:  Deepanshu Maheshwari; Dhananjay Kumar; Rakesh Kumar Jagdish; Nidhi Nautiyal; Ashinikumar Hidam; Rekha Kumari; Rashi Sehgal; Nirupama Trehanpati; Sukriti Baweja; Guresh Kumar; Swati Sinha; Meenu Bajpai; Viniyendra Pamecha; Chhagan Bihari; Rakhi Maiwall; Shiv Kumar Sarin; Anupam Kumar
Journal:  Front Immunol       Date:  2022-06-03       Impact factor: 8.786

Review 2.  Liver Transplantation as a Cornerstone Treatment for Acute-On-Chronic Liver Failure.

Authors:  Martin S Schulz; Wenyi Gu; Andreas A Schnitzbauer; Jonel Trebicka
Journal:  Transpl Int       Date:  2022-03-17       Impact factor: 3.842

3.  Reappraisal of sepsis-3 and CLIF-SOFA as predictors of mortality in patients with cirrhosis and infection presenting to the emergency department: A multicenter study.

Authors:  Ji Hyun Kim; Baek Gyu Jun; Minjong Lee; Hye Ah Lee; Tae Suk Kim; Jeong Won Heo; Da Hye Moon; Seong Hee Kang; Ki Tae Suk; Moon Young Kim; Young Don Kim; Gab Jin Cheon; Soon Koo Baik; Dong Joon Kim; Dae Hee Choi
Journal:  Clin Mol Hepatol       Date:  2022-05-06

4.  Immunomodulatory receptor VSIG4 is released during spontaneous bacterial peritonitis and predicts short-term mortality.

Authors:  Johanna Reißing; Philipp Lutz; Mick Frissen; Oluwatomi Ibidapo-Obe; Philipp A Reuken; Theresa H Wirtz; Sven Stengel; Stefanie Quickert; Michael Rooney; Karsten Große; Henning W Zimmermann; Christian Trautwein; Andreas Stallmach; Tony Bruns
Journal:  JHEP Rep       Date:  2021-11-03

Review 5.  Hepatorenal syndrome in acute-on-chronic liver failure with acute kidney injury: more questions requiring discussion.

Authors:  Songtao Liu; Qinghua Meng; Yuan Xu; Jianxin Zhou
Journal:  Gastroenterol Rep (Oxf)       Date:  2021-09-25

6.  COVID-19 mortality in cirrhosis is determined by cirrhosis-associated comorbidities and extrahepatic organ failure: Results from the multinational LEOSS registry.

Authors:  Jonathan F Brozat; Frank Hanses; Martina Haelberger; Melanie Stecher; Michael Dreher; Lukas Tometten; Maria M Ruethrich; Janne J Vehreschild; Christian Trautwein; Stefan Borgmann; Maria J G T Vehreschild; Carolin E M Jakob; Andreas Stallmach; Kai Wille; Kerstin Hellwig; Nora Isberner; Philipp A Reuken; Fabian Geisler; Jacob Nattermann; Tony Bruns
Journal:  United European Gastroenterol J       Date:  2022-04-28       Impact factor: 6.866

7.  Acute on chronic liver failure in cirrhosis.

Authors:  Marta Tonon; Salvatore Piano
Journal:  Clin Mol Hepatol       Date:  2022-02-14

8.  Characteristics of acute kidney injury and its impact on outcome in patients with acute-on-chronic liver failure.

Authors:  Yue Huang; Junjun Cai; Fushuang Ha; Beichen Guo; Shaojie Xin; Zhongping Duan; Tao Han
Journal:  BMC Gastroenterol       Date:  2022-05-11       Impact factor: 3.067

9.  Acute decompensation events differentially impact the risk of nosocomial infections and short-term outcomes in patients with cirrhosis.

Authors:  Xianbin Xu; Xia Yu; Kai Gong; Huilan Tu; Junjie Yao; Yan Lan; Shaoheng Ye; Haoda Weng; Yu Shi; Jifang Sheng
Journal:  Front Med (Lausanne)       Date:  2022-08-17

10.  Human Amnion-Derived Mesenchymal Stromal Cells: A New Potential Treatment for Carbapenem-Resistant Enterobacterales in Decompensated Cirrhosis.

Authors:  Mariangela Pampalone; Giampiero Vitale; Salvatore Gruttadauria; Giandomenico Amico; Gioacchin Iannolo; Bruno Douradinha; Alessandra Mularoni; Pier Giulio Conaldi; Giada Pietrosi
Journal:  Int J Mol Sci       Date:  2022-01-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.